cfo call insul
 rel insul led point out-performance
sinc outbreak defens drive
fundament improv legal resolut provid
compel catalyst emerg pandem
ceo seri weekli call c-suit execut across medic devic
field discuss key structur dynam invest debat recent
host wolk evp cfo johnson johnson theme discuss
focus fundament dynam includ guidanc
evid pharma acceler capit commit prioriti replay
pleas see insid detail discuss key takeaway johnson
daubert rule releas monday judg wolfson issu daubert rule
multi-district talc litig judg wolfson grant part three
expert request wherea deni three plaintiff request see daubert
earli take summari rule statement suggest compani
pleas judg wolfson certain limit plaintiff expert
testimoni fact rule limit expert testimoni
supplement earli take clearli increment posit
litig dilig suggest rule consist middle-of-the-road
expect overli surpris one expert spoke believ
daubert outcom could catalyst toward potenti settlement
reiter consid option evalu proceed trial vs
settlement note unlik case move trial next twelv
month opioid talc legal resolut better believ
reflect share late last year key compon upgrad thesi
insul clear underli fundament improv remain overweight
light dynam situat highlight key phase
invest stori investor look rel insul medic devic
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
 revenu pharma/consum sinc share
outperform devic point respect
vaccin develop provid addit benefit
sentiment perspect help off-set neg perspect surround
opioid/talc litig note increment step toward litig progress
and/or resolut may provid catalyst share beyond
convers provid confid pharma acceler thesi
key compon upgrad given greater rel insul combin
underli fundament improv still see attract risk/reward
setup current valuat rais price target base
ep in-lin
price target base multipl base case ep
support sotp analysi assum trade in-lin multipl
given defensive-ori prole growth acceler pharma andimprov fundament
consumer/md balanc litig overhang
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
litig liabil
reect share view creat
meaning valuat disconnect vs
pharma-driven acceler pois
drive multipl higher led
eas compar
momentum md consum
segment drive balanc
growth prole less reliant
consensu
view descript risk reward theme
impact mute across pharma
consum md impact less
sever anticip pharma organ
growth acceler high-singl digit
md consum demonstr
momentum oper leverag
gener lead sustain dd ep
growth make progress litig
process overhang gradual
remov share aggreg legal
liabil trade valuat
in-lin slight premium
major busi remain
rel insul impact
except md
blockbust franchis pipelin launch
contribut pharma acceler
drive multipl margin higher
progress aggreg liabil
valuat disconnect vs
narrow progress toward legal
settlement made
impact sever across
segment competit threat
biosimilar eros continu lead
lsd/msd growth pharma md
consum deceler y/i segment
revers cours leverag limit
driven incom gap neg
newsow opioid talc risperd
continu weigh share aggreg
legal liabil total trade
discount
progress toward litig settlement drive
narrow discount
blockbust pipeline-driven launch drive
pharma acceler point increment
pharma growth drive bp corpor
china india
view explan region hierarchi
research highest favor quintil
pharmaceut growth acceler hsd
opioid talc litig settl
litig overhang persist legal liabil
greater anticip
pharma pipelin unabl off-set biosimilar
competit risk
impact md sever
turnaround consum md fail
materi slower expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
updat supplement recent earn commentari receiv
increment updat transpar key dynam particularli
surround md guidanc algorithm vaccin progress
md algorithm discuss recap provid signific level
detail transpar md procedur impact recoveri model
built took one step call outlin detail
step assumpt compani use procedur model
although guidanc rang dramat widen compani
broader guidanc algorithm chang comfort reiter
vaccin develop leverag advac
technolog platform use develop vaccin ebola zika
hiv etc assum high degre confid success
one area manag share comfort consist prior commentari
manag state commerci unlik first-in-human dose
set septemb data expect respect manufactur
capac manag unwil specif outsid prior
commentari reiter dose capac run-rat
basi note simplist would impli dose end
frame procedur recoveri aforement procedur algorithm discuss
insid highli depend key variabl notabl viru longev
patient comfort macroeconom impact manag express optim
certain us state eu countri ie germani begin reopen economi
could potenti lead faster recoveri ramp origin assum
said hospit capac may becom barrier discuss procedur
model assum hospit extend hour perform elect surgeri day per week
capac would like increas discuss hospit exec survey
result consid surgeon fatigu conserv estim
taken appli certain region note modestli differ recoveri
algorithm net basi arriv similar conclus see look
discuss high level assumpt corpor revenu return
normal mr wolk express comfort strive better
recoveri algorithm hold
confid pharma acceler pharma organ growth beat
estim bp repres underli basi adjust one-
timer impact notabl impli bp underli momentum
acceler toughest comp year year year comp stabil
repres organ vs mse continu see blockbust
stelara darzalex imbruviva drive bp growth recent launch tremfya
erleada balversa spravato drive bp mr wolk declin comment
specif drug project optim convey recent momentum stelara
uc tremfya psoriasi erleada prostat cancer term headwind
price pressur exist new manag highlight biosimilar/gener
competit zytiga remicad prezista ou velcad ou tracleer us
see forecast declin bp headwind growth look ahead
compani confirm remain track key file approv ie darzalex
subcutan all-in came away earn cfo discuss
increment confid pharma acceler drive
multipl see
capit deploy thought state call activ
share repurchas program place compani plan announc new
program near-term rather compani priorit invest innov
dividend sustain compani aaa-rat balanc sheet
forecast year place compani stronger posit rel
larg cap coven concern arisen respect
mr wolk recogn devic valuat becom attract acquisit
perspect reason certain corpor may less will sell rather
view activ biopharma space like occur heighten level
first topic portfolio manag recal lower outlook
incom due delay plan divestitur given valuat
becom less desir compani continu look opportun
manag optim portfolio
cfo wolk provid addit detail data assumpt
compani use approach md guidanc addit see exhibit
excerpt compani earn present
understand case peak util variou sourc includ ihm
occur us across differ timelin throughout april late may
 european case peak mid-to-l april
 china peak week prior earn call earli april procedur began normal
estim patient stay week hospit base china proxi
estim hospit capac increas
assum hospit extend hour perform elect surgeri day per week
capac increas max
 conduct survey discuss hospit execut consid surgeon fatigu
 arriv addit capac like ad
 patient comfort schedul elect procedur
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig talent trial locat juri composit judg
composit investor contact legal advisor issu law relat
subject matter materi
